Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03919578
Other study ID # Hep B 0218
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date September 11, 2019
Est. completion date February 28, 2020

Study information

Verified date September 2022
Source PT Bio Farma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Protectivity and Safety Following Recombinant Hepatitis B Vaccine with different source of Hepatitis B bulk compared to Hepatitis B (Bio Farma) vaccine in Indonesian Population


Description:

Protectivity and Safety Following Recombinant Hepatitis B Vaccine with different source of Hepatitis B bulk compared to Hepatitis B (Bio Farma) vaccine in Indonesian Population. Experimental, randomized, double blind, four arm parallel group study, lot to lot consistency study.


Recruitment information / eligibility

Status Completed
Enrollment 536
Est. completion date February 28, 2020
Est. primary completion date January 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 10 Years to 40 Years
Eligibility Inclusion Criteria: 1. Healthy individu as determined by clinical judgment, including a medical history and physical exam which confirms the absence of a current or past disease state considered significant by the investigator. 2. Subjects/parents/guardian(s) have been informed properly regarding the study and signed the informed consent form/ informed assent form. 3. Subject/parents/guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial. Exclusion Criteria: 1. Subject concomitantly enrolled or scheduled to be enrolled in another trial. 2. Subjects with known history of Hepatitis B contained vaccination in the last 10 years 3. Evolving severe illness and/or chronic disease and fever (axillary temperature more than37.5oC) within the 48 hours preceding enrollment. 4. Known history of allergy to any component of the vaccines (based on anamnesis) 5. HBsAg positive 6. Known history of immunodeficiency disorder (HIV infection, leukemia, lymphoma, or malignancy). 7. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection. 8. Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or corticosteroid therapy and other immunosuppresant. 9. Pregnancy & Lactation (Adult) 10. Subject already immunized with any vaccine within 4 weeks prior and expects to receive other vaccines within 4 weeks following immunization.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Recombinant Hepatitis B vaccine
Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from Serum Institute of India and then formulated and filled at Bio Farma.
Recombinant Hepatitis B (Bio Farma)
Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from The Janssen Vaccine Corp and then formulated and filled at Bio Farma.

Locations

Country Name City State
Indonesia RSND Semarang Central Java

Sponsors (1)

Lead Sponsor Collaborator
PT Bio Farma

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of subjects with increasing antibody titer >= 4 times Percentage of subjects with increasing antibody titer >= 4 times: in all subjects; comparison between investigational product and control and between each lot number of Recombinant Hepatitis B 28 days after the last dose immunization
Secondary Geometric Mean Titer (GMT) GMT in all subjects; comparison of GMT between investigational products and control and comparison of GMT between each lot number of Recombinant Hepatitis B 28 days after the last dose immunization
Secondary Percentage of subjects with transition of seronegative to seropositive Percentage of subjects with transition of seronegative to seropositive: in all subjects; Subjets which get investigational products and control and each lot number of Recombinant Hepatitis B 28 days after the last dose immunization
Secondary Percentage of subjects with at least one immediate reaction Immediate reaction (local reaction or systemic event) 30 minutes after each vaccination
Secondary Percentage of subjects with at least one of these adverse events At least one of these adverse events, expected or not within 72 hours, between 72 hours to 28 days after vaccination
Secondary Serious adverse event after vaccination Serious adverse event occurring from inclusion until 28 days after vaccination. 28 days after the last dose immunization
Secondary Comparison adverse events between Investigational Products (Hepatitis B) and Control Adverse events occuring until 28 days after vaccination 28 days after each dose
Secondary Comparison of adverse events between each lot number of Recombinant Hepatitis B vaccine Adverse events occuring until 28 days after vaccination 28 days after each dose
See also
  Status Clinical Trial Phase
Completed NCT05383560 - Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults Phase 2
Recruiting NCT01763268 - Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Phase 2/Phase 3
Recruiting NCT05054621 - Immunogenicity of COVID-19 Vaccine on Heterologous Schedule Phase 2
Recruiting NCT05580159 - New Generation mRNA Booster Vaccine Against Emerging VOCs Phase 3
Active, not recruiting NCT05686161 - mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs Phase 3
Completed NCT04071379 - Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B Phase 3
Completed NCT01697007 - A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique Phase 2
Completed NCT03680417 - Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Phase 4
Completed NCT03722615 - Epidemiology of Congenital Cytomegalovirus in a High HIV Prevalence Setting, South Africa
Completed NCT01369927 - Shigella Sonnel O-SPC/rBRU Conjugate Vaccine Phase 1
Completed NCT04051268 - Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III) Phase 3
Recruiting NCT05115617 - Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Prospective Cohort Study
Not yet recruiting NCT05911087 - A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2 Phase 2/Phase 3
Completed NCT01092195 - Gardasil Vaccination in Post Stem Cell Transplant Patients Phase 1
Completed NCT01399853 - A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Phase 2
Completed NCT03460405 - Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants Phase 2
Completed NCT03681860 - EMaBS TB Vaccine Study Phase 1/Phase 2
Completed NCT04754698 - COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS Phase 4
Completed NCT04015232 - Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects. Phase 1
Recruiting NCT05150834 - Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines